Hemorrhagic Risk of Transrectal Ultrasound‐Guided Prostate Biopsy Under Continued Antithrombotic Therapy

TRUS-guided prostate biopsy under sacral anesthesia appeared feasible without discontinuation of antithrombotic therapy and was not associated with a clear excess of clinically significant hemorrhagic complications. In selected patients, particularly those at high thromboembolic risk, continuing antithrombotic therapy may be a reasonable option, although a modest increase in bleeding risk cannot be definitively excluded.